|
Email: f.gardiner@uq.edu.au
Research Interests
RA ('Frank') Gardiner is a consultant urologist at Royal
Brisbane and Women's Hospital. He has a longstanding commitments to
urological research and has worked particularly closely for many
years with Professors Martin Lavin (UQCCR & QIMR) and Suzanne
Chambers (Griffith University), as well as Drs John Yaxley (RBWH)
and Hema Samaratunga (Aquesta Pathology).
Together with Associate Professor Ken Pakenham (UQ Psychology),
he undertook the only randomised, controlled trial of androgen
deprivation therapy in prostate cancer, demonstrating significant
adverse cognitive as well as quality of life changes in treatment
compared with control (non-treatment) and community reference
men.
With Dr Chris Schmidt (QIMR), he ran the first two dendritic
cell vaccine trials in Australia for men with advanced prostate
cancer. His research focuses particularly on detection and
management of early prostate cancer, underpinned by a large 5-year
grant from Cancer Council Queensland of men randomised to robotic
or open prostatectomy, supported by colleagues in the Northern
Section of the Urological Society of Australia and New Zealand.
In a major change to practice, he initiated and promoted a
spirit of collaboration with researchers throughout Queensland
which involved the majority of Urologists in South East
Queensland and, amongst other activities, was previously a member
of a WHO-sponsored working party, a member of the founding
executive of Academic Surgeons of Asia, Chairman of the NHMRC
Clinical Careers Development Awards Committee and was a
member of the Australian Cancer Network Working Party for the
development of Clinical Practice Guidelines for the Management of
Advanced Prostate Cancer.
He instigated and initiated FingerTip Urology via www.bjui.org which presents in a
highly illustrated form, common presentations in urological
practice developed by experts around the world. The facility is
3-tiered, the lowermost tier being available to professionals and
the public free of charge and without a need to register. The slide
format is designed so that the resource can serve as a prop for
patient consultations as well as a learning resource for students.
Research Projects
Current studies
1. Early detection of prostate cancer:
Our group has pioneered research into non-invasive early
detection of prostate cancer using ejaculate. Our work is focussing
on
- Detection & Prognosis through RNA and protein
profiling
-
PCA3 & BMCC1 Biology
2. Randomised study robotic & open prostatectomy
trial:
We are undertaking the first randomised study of robotic and
open prostatectomy in a large collaborative study with colleagues
of the Northern Section of the Urological Society of Australia and
New Zealand and from other specialist disciplines locally and
interstate to
3. Psycho-social studies in prostate cancer:
In close collaboration with Adjunct Professor Chambers and
Northern Section colleagues, we are undertaking NHMRC-supported
prospective studies to
- Predict & promote long-term adjustment of men with
localised prostate cancer: ProsCan
- Randomised controlled trial of early intervention to improve
sexual & couple functioning after prostate cancer
|
Key Publications:
Clarke RA, Zhao Z, Guo A-Y, Roper K, Teng L, Fang Z-M,
Samaratunga H, Lavin MF, Gardiner RA. New Genomic
Structure for Prostate Cancer Specific Gene PCA3 within BMCC1:
Implications for prostate cancer detection and progression. Plos 1,
2009; 4:e4995
Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B,
Lavin MF, Gardiner RA. Identification of claudin-4
as a marker highly overexpressed in both primary metastatic
prostate cancer. BJ Cancer, 2008; 99:491-501
Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B,
Samaratunga H, Lavin MF, Gardiner
RA. Use of multiple biomarkers for a molecular
diagnosis of prostate cancer. Int J Cancer, 2005;114:950-956
Green HJ, Pakenham KI, Headley BA, Yaxley J, Nicol DL,
Mactaggart PN, Swanson C, Watson RB, Gardiner RA.
Altered cognitive function in men treated for prostate cancer with
luteinizing hormone-releasing hormone analogues and cyproterone
acetate: a randomised controlled trial. BJU Int, 2002;
90:427-32
Gardiner RA, Samaratunga MLTH, Gwynne RA,
Clague A, Seymour GJS and Lavin MF (1996). Abnormal prostatic cells
in ejaculates from men with prostatic cancer -a preliminary report.
Br J Urol, 1996; 78:414-8
Review/editorial:
Gardiner RA, Sweeney C, Tilley WD. Editorial:
Testosterone Therapy in Castrate Resistant Prostate Cancer: a
possible new approach. Eur Urol, 2009; 56:245-6
|
Collaborations
Professor Rob Carter (Deakin University, Melbourne)
Dr Scott Williams (Peter Macallum Cancer Centre, Melbourne)
Dr Stefano Occhipinti (Griffith University, Brisbane)
Dr Horst Schirra (School of Chemistry and Molecular Biosciences
University of Queensland)
Dr Terry Walsh (Queensland University of Technology,
Brisbane)
Dr Christoph Zenzmaier (Institute for Biomedical Aging Research,
Austrian Academy of Sciences)
Professor Rob Newton Edith Cowan University Western
Australia
Dr David MacFarlane, Deputy Director of nuclear Medicine, Royal
Brisbane & Women's Hospital
|
